DoH Policies screened during the period: 1st October 2019-31st December 2019
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- NICE Technology Appraisal TA562 - Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
- NICE Technology Appraisal TA563 - Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
- NICE Technology Appraisal TA565 - Benralizumab for treating severe eosinophilic asthma
- NICE Technology Appraisal TA566 - Cochlear implants for children and adults with severe to profound deafness
- NICE Technology Appraisal TA571 - Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
- NICE Technology Appraisal TA583 - Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
- NICE Technology Appraisal TA584 - Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
- NICE Technology Appraisal TA585 - Ocrelizumab for treating primary progressive multiple sclerosis
- NICE Technology Appraisal TA599 - Sodium zirconium cyclosilicate for treating hyperkalaemia
- NICE Clinical Guideline NG115 - Chronic obstructive pulmonary disease in over 16s: diagnosis and management (updates and replaces CG101)
- NICE Technology Appraisal TA572 - Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
- NICE Technology Appraisal TA592 - Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
- NICE Technology Appraisal TA597 - Dapagliflozin with insulin for treating type 1 diabetes
- NICE Technology Appraisal TA590 - Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
- NICE Technology Appraisal TA591 - Letermovir for preventing cytomegalovirus disease after a stem cell transplant
- NICE Technology Appraisal TA593 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
- NICE Technology Appraisal TA596 - Risankizumab for treating moderate to severe plaque psoriasis
- NICE Technology Appraisal TA604 - Idelalisib for treating refractory follicular lymphoma
- NICE Technology Appraisal TA575 - Tildrakizumab for treating moderate to severe plaque psoriasis
- NICE Technology Appraisal TA577 - Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
- NICE Technology Appraisal TA578 - Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
- NICE Technology Appraisal TA579 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine
- NICE Technology Appraisal TA580 - Enzalutamide for hormone-relapsed non-metastatic prostate cancer
- NICE Technology Appraisal TA581 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
- NICE Technology Appraisal TA586 - Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
- NICE Technology Appraisal TA587 - Lenalidomide plus dexamethasone for previously untreated multiple myeloma
- NICE Technology Appraisal TA588 - Nusinersen for treating spinal muscular atrophy
- NICE Technology Appraisal TA589 - Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
- NICE Technology Appraisal TA595 - Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
- NICE Technology Appraisal TA598 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
- NICE Technology Appraisal TA600 - Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
- NICE Technology Appraisal TA610 - Pentosan polysulfate sodium for treating bladder pain syndrome
- NICE Technology Appraisal TA605 - Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
- NICE Technology Appraisal TA606 - Lanadelumab for preventing recurrent attacks of hereditary angioedema
- NICE Technology Appraisal TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
- NICE Technology Appraisal TA611 - Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
- NICE Clinical Guideline NG116 - Post-traumatic stress disorder (updates and replaces CG26)
- NICE Clinical Guideline NG118 - Renal and ureteric stones: assessment and management
- NICE Technology Appraisal TA612 - Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
- NICE Clinical Guideline NG119 - Cerebral palsy in adults
- NICE Technology Appraisal TA613 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (part review of TA301)